Avinger (NASDAQ:AVGR) Receives New Coverage from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Avinger (NASDAQ:AVGR) in a research report released on Sunday morning. The brokerage issued a hold rating on the medical device company’s stock.

Separately, HC Wainwright restated a buy rating and set a $5.00 target price on shares of Avinger in a research note on Thursday, March 21st.

Avinger Price Performance

Shares of AVGR stock opened at $2.60 on Friday. Avinger has a 1 year low of $2.50 and a 1 year high of $18.00. The firm has a fifty day moving average price of $3.49 and a 200-day moving average price of $3.21. The company has a market cap of $4.42 million, a price-to-earnings ratio of -0.14 and a beta of 1.22.

Avinger (NASDAQ:AVGR) last released its earnings results on Wednesday, March 20th. The medical device company reported ($3.93) earnings per share for the quarter, missing analysts’ consensus estimates of $0.64 by ($4.57). The company had revenue of $1.91 million for the quarter, compared to the consensus estimate of $2.52 million. Equities research analysts expect that Avinger will post -2.08 EPS for the current year.

Avinger Company Profile

Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.